RxDoctor Payments Data

Aliza Mazhar, MD

Family Medicine · Zionsville, INNPI 1417454505

Payments from drug & device makers

$585in general payments, 2019–2025

Across 27 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$138
  • Pfizer$116
  • GSK$108
  • Amgen$64
  • Exact Sciences$57
  • Lilly USA, LLC$26
  • plus $76 from 4 others

What the payments were for

  • Food & beverage$585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk2$138
Pfizer7$116
GSK6$108
Amgen3$64
Exact Sciences3$57
Lilly USA, LLC2$26
Abbott1$23
Dexcom, Inc.1$21
Medtronic1$19
Si-bone, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$585 in reported general payments places this provider in the 50th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$73,461
Medicare patients
261
Services billed
908

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban175$61,665
OzempicSemaglutide32$39,909
TrulicityDulaglutide39$39,401
JardianceEmpagliflozin62$36,269
MounjaroTirzepatide21$22,957
XareltoRivaroxaban31$8,746
FarxigaDapagliflozin Propanediol12$6,123
Breo ElliptaFluticasone/Vilanterol15$6,047
Tresiba Flextouch U-100Insulin Degludec20$5,754
QuliptaAtogepant11$5,649
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$4,515
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,181
Memantine Hcl90$4,125
Atorvastatin Calcium343$3,694
ShingrixVaricella-Zoster Ge/As01b/Pf15$3,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30$26$64,02874 claims
PfizerEliquis$116$61,665175 claims
Novo NordiskOzempic$138$39,90932 claims
GSKBreo Ellipta, Shingrix$108$9,27930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Zionsville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →